Bi-sept-Farmak( sulfamethoxazole, trimethoprim)

Bi-sept-Pharmac( sulfamethoxazole, trimethoprim) Instruction:

Manufacturer:

Active substances Bi-SepT-Pharmac:

Form of Bi-sept-Pharmac:

Tablets( 400 mg / 80 mg) No. 10, No. 10x2, No.20 in contour cell packs.

Who is BeeChT-Farmak shown?

Infectious-inflammatory diseases caused by drug-susceptible microorganisms:

  • infections of the kidneys and urinary tract: acute and chronic urethritis, cystitis, pyelonephritis, genital tract infections: post-natal urethritis, prostatitis, gonorrheal epididymitis, acute and chronic gonorrhea;
  • acute inflammation of the middle ear, osteomyelitis;meningitis, brain abscess;
  • respiratory tract infections: tonsillitis, laryngitis, acute and chronic bronchitis, bronchiectasis, pneumonia;bacteriologically confirmed pneumonia, the causative agent of which is Pneumocystis carinii, and the prevention of infection with this microorganism in patients with signs of increased risk( eg, AIDS);
  • scarlet fever, brucellosis, digestive tract infections: typhoid fe
    ver, paratyphoid, bacterial dysentery, cholera( as part of combination therapy), acute gastroenteritis, chronic colitis of unclear etiology, cholecystitis, cholangitis;
  • skin and soft tissue infections: furunculosis, impetigo, erysipelas, purulent folliculitis, abscesses, acne, infected wounds;
  • toxoplasmosis( as part of combination therapy), nocardiosis;
  • sepsis.

How to use Bi-sept-Farmak?

Adults and children over 12 years of age are prescribed 2 B-SepT-Farmak tablets 2 times a day. For long-term therapy appoint 1 tablet 2 times a day( for the prevention of recurrences of chronic infections).Children from 6 to 12 years are prescribed 1 tablet of Bi-SepT-Farmak 2 times a day, from 3 to 6 years - 1/2 tablets B-SepT-Farmak 2 times a day. To prevent the recurrence of chronic infections, B-sept-Farmak is used for 3-12 months. The drug should be taken at intervals of 12 hours, preferably after eating, washing it with several glasses of liquid. In acute infections, the duration of treatment is 6-14 days, with acute brucellosis -3-4 weeks, with typhoid fever and paratyphoid - 1-3 months. Patients with a creatinine clearance of 15-30 ml / min. The dose of Bi-SepT-Farmak should be reduced by half. If the creatinine clearance is less than 15 ml / min, the drug is not prescribed. Inflammation of the urinary tract and middle ear in children: usually prescribed 48 mg / kg of body weight per day in 2 doses with an interval of 12 hours. To treat gonorrhea B-sept-Farmak prescribed in a dose of 1.92-2.88 g( 4-6 tablets), which is taken in 3 divided doses at intervals of 12 hours. With gonorrheal pharyngitis, in case of hypersensitivity to penicillin, B-SepT-Farmak is prescribed in a dose of 4.32 g( 9 tablets) once a day for 5 days. Pneumonia caused by pneumonia in adults and children: the recommended dose for people with confirmed inflammation is 90-120 mg / kg body weight per day in doses that need to be taken every 6 hours for 14-21 days. Children should be taken with food or immediately after eating 1/2 pills Bi-SepT-Farmak 2 times a day. The course of treatment is from 5 to 14 days.

It is not recommended to prescribe Bi-sept-Farmak to children under the age of 3 years, as well as pregnant women and women breast-feeding. If the renal function is impaired, a dose adjustment of Bi-septa-Farmak should be performed.

Special Disclaimer. If symptoms occur during B-Sept-Pharmac treatment that indicate the possibility of complications, especially rash, sore throat, fever, joint pain, cough, shortness of breath, jaundice, micturition, edema, back pain, stop using the drug. Admission Bi-sept-Farmak with streptococcal throat inflammation often ends in failure, as it can not destroy bacteria. In elderly patients, the risk of severe B-SepT-Pharmacal side effects( kidney or liver damage, severe skin reactions, inhibition) increases. In AIDS patients who take Bisept-Pharmac, symptoms such as rash, fever, leukopenia, increased levels of aminotransferases, hypokalemia and hyponatremia are more common. Caution should be given to patients with severe impairment of liver or kidney function, lack of folic acid( eg, elderly people, alcoholics, people who are treated with anticonvulsant drugs, people with malabsorption syndrome and malnutrition), severe allergic reactions, asthma, andpatients with a decreased activity of the enzyme glucose-6-phosphate dehydrogenase.

Side effects of Bi-sept-Pharmac.

The most common problems are with the digestive tract( nausea, vomiting, lack of appetite) and skin( rash, hives, polymorphic erythema, skin itching).There may be pseudomembranous colitis, pancreatitis, thrombophlebitis, arthralgia, myalgia. Rarely can conditions occur that are life-threatening: Shenlaine-Henoch syndrome, Lyell syndrome, acute liver necrosis, aplastic anemia, hemolytic anemia, megaloblastic anemia, agranulocytosis, eosinophilia, thrombocytopenia, methemoglobinemia, hypoprothrombinemia and other bone marrow damage.

Who is contraindicated in Bi-SepT-Farmak?

Hypersensitivity to the drug. Megaloblastic anemia caused by a lack of folic acid. Pregnancy and lactation. Children under 3 years of age.

Interaction of Bi-sept-Farmak.

In elderly patients, the simultaneous use of B-SepT-Pharmac with certain diuretics, especially thiazides, increases the risk of bone marrow damage. Bi-sept-Farmak can enhance the effect of indirect anticoagulants, enhances the hypoglycemic effect of sulfonamides, which requires a reduction in the dose of this drug. Bi-sept-Farmak inhibits the metabolism of phenytoin, as a result of which the action of phenytoin is prolonged. Bi-sept-Farmak can enhance the effect of methotrexate, increase the level of cyclosporine in the blood plasma, enhancing its nephrotoxicity.

Overdose of Bi-sept-Pharmac.

In acute overdose of the drug, there is a lack of appetite, nausea, vomiting, headache, drowsiness, loss of consciousness. In case of an overdose of the drug, it is necessary to rinse the stomach or induce vomiting, take a large amount of fluid, if necessary, carry out symptomatic treatment. In chronic overdose, oppression of hematopoiesis( thrombocytopenia, leukopenia) is observed.